全文获取类型
收费全文 | 128篇 |
免费 | 8篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 2篇 |
妇产科学 | 2篇 |
基础医学 | 17篇 |
口腔科学 | 3篇 |
临床医学 | 14篇 |
内科学 | 25篇 |
皮肤病学 | 1篇 |
神经病学 | 4篇 |
外科学 | 13篇 |
综合类 | 4篇 |
预防医学 | 7篇 |
药学 | 21篇 |
中国医学 | 1篇 |
肿瘤学 | 23篇 |
出版年
2023年 | 6篇 |
2022年 | 6篇 |
2021年 | 3篇 |
2020年 | 8篇 |
2019年 | 3篇 |
2018年 | 8篇 |
2017年 | 5篇 |
2016年 | 5篇 |
2015年 | 4篇 |
2014年 | 10篇 |
2013年 | 6篇 |
2012年 | 10篇 |
2011年 | 14篇 |
2010年 | 4篇 |
2009年 | 4篇 |
2008年 | 6篇 |
2007年 | 5篇 |
2006年 | 7篇 |
2005年 | 6篇 |
2004年 | 8篇 |
2003年 | 5篇 |
2002年 | 1篇 |
1991年 | 1篇 |
1989年 | 1篇 |
1967年 | 1篇 |
排序方式: 共有137条查询结果,搜索用时 31 毫秒
1.
Tejaswini Parlapalle Reddy Usman Khan Ethan Alexander Burns Maen Abdelrahim 《World journal of clinical oncology》2020,11(11):959-967
BACKGROUNDColorectal cancer (CRC) is the third leading cause of cancer-related death in males and females in the United States. Approximately, 20%-22% of patients have metastatic disease at the time of presentation, and 50%-60% will develop metastasis over the course of their disease. Despite advances in systemic therapies, there remains a paucity of effective third- and later-line therapies for patients with ongoing disease progression. However, rechallenging chemo-resistant CRC tumors with previously administered therapies is an emerging concept that may be a life-prolonging option for heavily treated metastatic colorectal cancer (mCRC).CASE SUMMARYA 41-year-old man with no previous medical history initially presented with worsening diffuse abdominal tenderness. Computed tomography was significant for a splenic flexure mass and hepatic lesions concerning for metastatic disease. He underwent a colectomy with anastomosis. Postoperative pathology was diagnostic for moderately to well-differentiated adenocarcinoma (T4bN1bM1a). He received adjuvant 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX), but therapy was discontinued due to the development of atrial fibrillation. Additional workup indicated a carcinoembryonic antigen level of 508.2 ng/mL, and mutational analysis found that the tumor was microsatellite instability-high and KRAS/BRAF wild-type. He was started on irinotecan with oxaliplatin (IROX), and bevacizumab (14 cycles), developed disease progression, was transitioned to FOLFOX and cetuximab, and then eventually three cycles of pembrolizumab. Following disease progression, he was rechallenged with IROX therapy, as he previously responded well to oxaliplatin-based therapy. The IROX rechallenge provided this patient with a ten-month survival benefit, decreased metastatic burden, and marked improvement in his clinical condition.CONCLUSIONRechallenge of previous lines of well-tolerated systemic chemotherapy regimens may be a valuable therapeutic strategy in patients with heavily-treated mCRC. 相似文献
2.
Johanna C. Bendell Tamara Sauri Antonio Cubillo Gracián Rafael Alvarez Carlos López-López Pilar García-Alfonso Maen Hussein Maria-Luisa Limon Miron Andrés Cervantes Clara Montagut Cristina Santos Vivas Alberto Bessudo Patricia Plezia Veerle Moons Johannes Andel Jaafar Bennouna Andre van der Westhuizen Leslie Samuel Simona Rossomanno Christophe Boetsch Angelika Lahr Izolda Franjkovic Florian Heil Katharina Lechner Oliver Krieter Herbert Hurwitz for the McCAVE Study Group 《The oncologist》2020,25(3):e451-e459
3.
Babiker Hani M. Milhem Mohammed Aisner Joseph Edenfield William Shepard Dale Savona Michael Iyer Swaminathan Abdelrahim Maen Beach C. L. Skikne Barry Laille Eric Tsai Kao-Tai Ho Thai 《Cancer chemotherapy and pharmacology》2020,85(3):621-626
Cancer Chemotherapy and Pharmacology - CC-486 is an oral formulation of azacitidine that allows for extended dosing schedules to prolong azacitidine exposure to malignant cells and maximize... 相似文献
4.
1,1-Bis(3'-indolyl)-1-(p-t-butylphenyl)methane (DIM-C-pPhtBu) is a peroxisome proliferator-activated receptor gamma (PPARgamma) agonist, and treatment of SKOV3 ovarian cancer cells with this compound (5 micromol/L) inhibits cell proliferation, whereas up to 15 micromol/L rosiglitazone had no effect on cell growth. DIM-C-pPhtBu also inhibits G0-G1 to S phase cell cycle progression and this is linked, in part, to PPARgamma-dependent induction of the cyclin-dependent kinase inhibitor p21. DIM-C-pPhtBu induces PPARgamma-independent down-regulation of cyclin D1 and we therefore further investigated activation of receptor-independent pathways. DIM-C-pPhtBu also induced apoptosis in SKOV3 cells and this was related to induction of glucose-related protein 78, which is typically up-regulated as part of the unfolded protein response during endoplasmic reticulum (ER) stress. Activation of ER stress was also observed in other ovarian cancer cell lines treated with DIM-C-pPhtBu. In addition, DIM-C-pPhtBu induced CCAAT/enhancer binding protein homologous protein through both ER stress and c-jun NH2-terminal kinase-dependent pathways, and CCAAT/enhancer binding protein homologous protein activated death receptor 5 and the extrinsic pathway of apoptosis. These results show that DIM-C-pPhtBu inhibits growth and induces apoptosis in ovarian cancer cells through both PPARgamma-dependent and PPARgamma-independent pathways, and this complex mechanism of action will be advantageous for future clinical development of these compounds for treatment of ovarian cancer. 相似文献
5.
6.
1,1-Bis(3'-indolyl)-1-(p-trifluoromethylphenyl)methane (DIM-C-pPhCF3) and troglitazone activate peroxisome proliferator-activated receptor gamma (PPARgamma) in Panc-28 pancreatic cancer cells and also inhibit cell proliferation. DIM-C-pPhCF3 was more active than troglitazone and was used as a model to investigate the mechanism of PPARgamma-dependent inhibition of Panc-28 cell growth. DIM-C-pPhCF3 significantly inhibited G0/G1-->S phase progression, as determined by FACS analysis, and this was associated with decreased retinoblastoma protein phosphorylation and increased p21 protein and mRNA expression, but no change in p27 or cyclin D1. PPARgamma antagonists blocked DIM-C-pPhCF3-induced growth inhibition and induction of p21 protein, and similar inhibitory effects were observed in Panc-28 cells transfected with a construct (pWWP) containing a -2325 to +8 p21 promoter insert. Deletion analysis of the p21 promoter indicated that PPARgamma-dependent activation of p21 promoter constructs by DIM-C-pPhCF3 required GC-rich sites 3 and 4 in the proximal region (-124 to -60) of the p21 promoter. The results of RNA interference and protein expression/DNA binding assays suggest that DIM-C-pPhCF3 induced p21 expression through a novel mechanism that involves PPARgamma interactions with both Sp1 and Sp4 proteins bound to the proximal GC-rich region of the p21 promoter. 相似文献
7.
8.
Shin TM Bril V Orszag A Ahmed A Perkins BA 《Diabetes research and clinical practice》2011,92(1):e16-e19
We examined the impact of variation in the interpretation of published guidelines for polyneuropathy diagnosis in type 1 diabetes. Though insensitive to clinical criteria, results indicated that case definition was substantially influenced by variation in electrophysiological criteria emphasizing the need for research into targeted algorithms for incorporation into future guidelines. 相似文献
9.
Hume DA Lovblom LE Ahmed A Yeung E Orszag A Shin TM Bril V Perkins BA 《Diabetes research and clinical practice》2012,95(2):e37-e40
We investigated the association of CDKAL1 (rs7754840 and rs7756992) and CDKN2A/2B (rs10811661) variants with T2DM. Higher MAF of rs7754840 and rs7756992 were seen in patients, and both were associated with T2DM under additive, dominant, and recessive models. CDKAL1 rs7754840 and rs7756992, but not CDKN2A/2B rs10811661, are associated with T2DM in Lebanese. 相似文献
10.
Faris MoezAlIslam E. Vitiello Michael V. Abdelrahim Dana N. Cheikh Ismail Leila Jahrami Haitham A. Khaleel Sharfa Khan Maryam S. Shakir Ayman Z. Yusuf Ayesha M. Masaad Alyaa A. Bahammam Ahmed S. 《Sleep & breathing》2022,26(3):1365-1376
Sleep and Breathing - This study investigated the relationships between eating habits and sleep quality among university students. In a cross-sectional study, university students completed a... 相似文献